Printer Friendly

US Medical Device Tax Moratorium Prompts Masimo to Pledge Increased Spending on R/D.

M2 PHARMA-December 18, 2015-US Medical Device Tax Moratorium Prompts Masimo to Pledge Increased Spending on R/D


- US-based patient monitoring technologies specialist Masimo (NASDAQ: MASI) will increase investment in infrastructure and research and development in response to the moratorium on the US Medical Device Tax, the company said on Friday.

Massimo said that the Medical Device Tax of 2013, which was part of the US Affordable Care Act (Obamacare), became an impediment to innovation that springs from start-ups, and many established companies curtailed their investments in research and development and reduced their workforces to pay the new revenue tax.

The US congress this week passed a moratorium suspending the tax, which had been meant to raise USD 30bn over ten years to pay for Obamacare. The tax will now be suspended for 2016 and 2017.

Masimo offers noninvasive monitoring devices. In 1995, the company debuted Masimo SET Measure-through Motion and Low Perfusion pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms.

In 2005, Masimo introduced rainbow Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and more recently, Pleth Variability Index and Oxygen Reserve Index, in addition to SpO2, pulse rate, and perfusion index.

Then, in 2014, Masimo introduced Root, an intuitive open architecture patient monitoring and connectivity platform designed to speed the pace of innovation and reduce the cost of care.

Masimo is also active in mHealth with products such as the Radius-7 wearable patient monitor and the MightySat fingertip pulse oximeter.

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 18, 2015
Previous Article:AlloSource Receives US Patent for Flagship Cellular Bone Allograft Product.
Next Article:BiO2 Medical Completes Pivotal Clinical Trial of Angel Catheter.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters